Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

PAI-1 donor polymorphism influences long-term kidney graft survival.

Rérolle JP, Munteanu E, Drouet M, Szelag JC, Champtiaux B, Yagoubi F, Preux PM, Aldigier JC, Le Meur Y.

Nephrol Dial Transplant. 2008 Oct;23(10):3325-32. doi: 10.1093/ndt/gfn241.

PMID:
18463321
2.

Plasminogen activator inhibitor-1 polymorphism is associated with progressive renal dysfunction after acute rejection in renal transplant recipients.

Chow KM, Szeto CC, Szeto CY, Poon P, Lai FM, Li PK.

Transplantation. 2002 Dec 27;74(12):1791-4.

PMID:
12499900
3.

Impact of donor-dependent genetic factors on long-term renal graft function.

Krajewska M, Kościelska-Kasprzak K, Weyde W, Drulis-Fajdasz D, Madziarska K, Mazanowska O, Kusztal M, Klinger M.

Transplant Proc. 2009 Oct;41(8):2978-80. doi: 10.1016/j.transproceed.2009.08.027.

PMID:
19857655
4.

Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients.

Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, Marti HP, Ganz R, Frey FJ, Kohler HP.

Transplantation. 2002 Oct 27;74(8):1147-52.

PMID:
12438962
5.

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.

Castelló R, España F, Vázquez C, Fuster C, Almenar SM, Aznar J, Estellés A.

Thromb Res. 2006;117(5):487-92.

PMID:
15907980
6.

Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.

Onalan O, Balta G, Oto A, Kabakci G, Tokgozoglu L, Aytemir K, Altay C, Gurgey A, Nazli N.

J Thromb Thrombolysis. 2008 Dec;26(3):211-7.

PMID:
17721742
8.

Chronic graft dysfunction in renal transplant patients: potential role of plasminogen activator inhibitor type 1.

Lahlou A, Peraldi MN, Thervet E, Flahault A, Delarue F, Soubrier F, Rossert J, Hertig A, Rondeau E.

Transplantation. 2002 Apr 27;73(8):1290-5.

PMID:
11981424
9.
10.

Genetic interactions between the donor and the recipient for susceptibility to acute rejection in kidney transplantation: polymorphisms of CCR5.

Cha RH, Yang SH, Kim HS, Kim SM, Park MH, Ha J, Kim YS.

Nephrol Dial Transplant. 2009 Sep;24(9):2919-25. doi: 10.1093/ndt/gfp317.

PMID:
19561149
11.
12.

The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study.

Juhan-Vague I, Morange PE, Frere C, Aillaud MF, Alessi MC, Hawe E, Boquist S, Tornvall P, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Humphries SE; HIFMECH Study Group..

J Thromb Haemost. 2003 Nov;1(11):2322-9.

13.

Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.

Jorgenson E, Deitcher SR, Cicek M, Liu X, Plummer S, Casey G, Witte JS.

Prostate. 2007 Feb 1;67(2):172-7.

PMID:
17044080
14.

Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.

Ezzidi I, Mtiraoui N, Chaieb M, Kacem M, Mahjoub T, Almawi WY.

Diabetes Metab. 2009 Jun;35(3):214-9. doi: 10.1016/j.diabet.2008.12.002.

15.

Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression.

Ramón LA, Gilabert-Estellés J, Cosín R, Gilabert J, España F, Castelló R, Chirivella M, Romeu A, Estellés A.

Thromb Res. 2008;122(6):854-60. doi: 10.1016/j.thromres.2008.02.010.

PMID:
18423526
16.

Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.

Zietz B, Buechler C, Drobnik W, Herfarth H, Schölmerich J, Schäffler A.

Endocr Res. 2004 Aug;30(3):443-53.

PMID:
15554360
17.

PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.

Meigs JB, Dupuis J, Liu C, O'Donnell CJ, Fox CS, Kathiresan S, Gabriel SB, Larson MG, Yang Q, Herbert AG, Wilson PW, Feng D, Tofler GH, Cupples LA.

Obesity (Silver Spring). 2006 May;14(5):753-8.

18.

The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.

Pérez-Martínez P, Adarraga-Cansino MD, Fernández de la Puebla RA, Blanco-Molina A, Delgado-Lista J, Marín C, Ordovás JM, López-Miranda J, Pérez-Jiménez F.

Br J Nutr. 2008 Apr;99(4):699-702.

PMID:
17903340
19.

The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease.

Sans M, Tàssies D, Pellisé M, Espinosa G, Quintó L, Piqué JM, Reverter JC, Panés J.

Aliment Pharmacol Ther. 2003 Apr;17(8):1039-47.

20.

The impact of eNOS, MTR and MTHFR polymorphisms on renal graft survival in children and young adults.

Artifoni L, Benetti E, Centi S, Negrisolo S, Ghiggeri GM, Ginevri F, Ghio L, Edefonti A, Brambilla C, Cagni N, Murer L.

Nephrol Dial Transplant. 2009 Sep;24(9):2931-7. doi: 10.1093/ndt/gfp161.

PMID:
19349296
Items per page

Supplemental Content

Support Center